Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Rectal cancer
Stage/Subtype:  stage III rectal cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 60 for your search:
Start Over
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: NL36315.042.11, NCI-2014-01600, 2010-023957-12, NCT01558921
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.52, NCI-2014-02486, 2012-000095-42, NCT02149108
Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: Neogenix 0901, NCI-2012-01393, NCT01040000
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
Cyclodextrin-Based Polymer-Camptothecin CRLX10, Capecitabine, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced Rectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1315, NCI-2014-00897, NCT02010567
Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-505, NCI-2014-00461, 9525, NCT02079740
Pembrolizumab and Combination Chemotherapy in Treating Patients with Advanced Colorectal, Gastroesophageal, Pancreatic, or Biliary Tract Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI76239, NCI-2015-00123, 3475-085, 76239, MK-3475 GI, NCT02268825
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-02, NCI-2015-00273, NCT02335918
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CPDR001X2101, NCI-2015-00577, 2014-003929-17, NCT02404441
A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PLX120-03, NCI-2015-00720, NCT02428712
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Exercise and Metformin Hydrochloride in Lowering Insulin Levels in Colorectal or Breast Cancer Survivors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training, Treatment
Age: 18 and over
Trial IDs: 11-009, NCI-2011-02702, NCT01340300
Gemcitabine Hydrochloride and Docetaxel in Treating Patients with Relapsed or Refractory Colorectal Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: J1214, NCI-2012-01337, NCI-2013-01567, NCT01639131
Ziv-Aflibercept and Combination Chemotherapy in Treating Patients with Previously Untreated Colorectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 11182, NCI-2012-01167, 2012C0055, NCT01652196
Dovitinib Lactate in Treating Patients with Previously Treated Advanced Non-Small Cell Lung Cancer or Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCDCC#231, NCI-2013-01182, 344991, 344991-6, CTKI258AUS21T, NCT01676714
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116833, NCI-2014-00142, NCT01750918
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-224, NCI-2014-01095, NCT01776307
Akt Inhibitor MK2206 in Treating Patients with Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2012-0431, NCI-2013-00487, 9340, NCT01802320
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin before Surgery in Treating Patients with Stage II-III Rectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3R-12-2, NCI-2013-01069, 3C-12-2, HS-12-00726, ML28263, NCT01871571
Pembrolizumab in Treating Patients with Metastatic or Locally Advanced Microsatellite Unstable Solid Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J1365, NCI-2013-02436, CIR00001187, MK-3475-016, NA_00085756, NA_00085756 / CIR00007001, NCT01876511
Chemotherapy before or after Chemoradiation Followed by Surgery or Non-operative Management in Treating Patients with Previously Untreated Stage II-III Rectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-213, NCI-2013-02356, NCT02008656
Start Over